Your browser doesn't support javascript.
loading
SARS-CoV-2 clade dynamics and their associations with hospitalisations during the first two years of the COVID-19 pandemic.
Päll, Taavi; Abroi, Aare; Avi, Radko; Niglas, Heiki; Shablinskaja, Arina; Pauskar, Merit; Jõgeda, Ene-Ly; Soeorg, Hiie; Kallas, Eveli; Lahesaare, Andrio; Truusalu, Kai; Hoidmets, Dagmar; Sadikova, Olga; Ratnik, Kaspar; Sepp, Hanna; Dotsenko, Liidia; Epstein, Jevgenia; Suija, Heleene; Kaarna, Katrin; Smit, Steven; Milani, Lili; Metspalu, Mait; Oopkaup, Ott Eric; Koppel, Ivar; Jaaniso, Erik; Kuzmin, Ivan; Inno, Heleri; Raudvere, Uku; Härma, Mari-Anne; Naaber, Paul; Reisberg, Tuuli; Peterson, Hedi; Talas, Ulvi Gerst; Lutsar, Irja; Huik, Kristi.
Afiliación
  • Päll T; Department of Microbiology, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Abroi A; Faculty of Science and Technology, Institute of Technology, University of Tartu, Tartu, Estonia.
  • Avi R; Department of Microbiology, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Niglas H; Department of Communicable Diseases, Health Board, Tallinn, Estonia.
  • Shablinskaja A; Department of Microbiology, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Pauskar M; Department of Microbiology, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Jõgeda EL; Department of Microbiology, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Soeorg H; Department of Microbiology, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Kallas E; Department of Microbiology, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Lahesaare A; SYNLAB Eesti OÜ, Tallinn, Estonia.
  • Truusalu K; Department of Microbiology, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Hoidmets D; Department of Microbiology, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Sadikova O; Department of Communicable Diseases, Health Board, Tallinn, Estonia.
  • Ratnik K; SYNLAB Eesti OÜ, Tallinn, Estonia.
  • Sepp H; Department of Communicable Diseases, Health Board, Tallinn, Estonia.
  • Dotsenko L; Department of Communicable Diseases, Health Board, Tallinn, Estonia.
  • Epstein J; Department of Communicable Diseases, Health Board, Tallinn, Estonia.
  • Suija H; Department of Communicable Diseases, Health Board, Tallinn, Estonia.
  • Kaarna K; Clinical Research Centre, Faculty of Medicine, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
  • Smit S; Tartu University Hospital, Tartu, Estonia.
  • Milani L; Institute of Genomics, Faculty of Science and Technology, University of Tartu, Tartu, Estonia.
  • Metspalu M; Institute of Genomics, Faculty of Science and Technology, University of Tartu, Tartu, Estonia.
  • Oopkaup OE; Institute of Genomics, Faculty of Science and Technology, University of Tartu, Tartu, Estonia.
  • Koppel I; High Performance Computing Centre, Faculty of Science and Technology, Institute of Computer Science, University of Tartu, Tartu, Estonia.
  • Jaaniso E; High Performance Computing Centre, Faculty of Science and Technology, Institute of Computer Science, University of Tartu, Tartu, Estonia.
  • Kuzmin I; Institute of Computer Science, Faculty of Science and Technology, University of Tartu, Tartu, Estonia.
  • Inno H; High Performance Computing Centre, Faculty of Science and Technology, Institute of Computer Science, University of Tartu, Tartu, Estonia.
  • Raudvere U; High Performance Computing Centre, Faculty of Science and Technology, Institute of Computer Science, University of Tartu, Tartu, Estonia.
  • Härma MA; High Performance Computing Centre, Faculty of Science and Technology, Institute of Computer Science, University of Tartu, Tartu, Estonia.
  • Naaber P; Department of Communicable Diseases, Health Board, Tallinn, Estonia.
  • Reisberg T; Department of Microbiology, Faculty of Medicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Peterson H; SYNLAB Eesti OÜ, Tallinn, Estonia.
  • Talas UG; Institute of Genomics, Faculty of Science and Technology, University of Tartu, Tartu, Estonia.
  • Lutsar I; Institute of Computer Science, Faculty of Science and Technology, University of Tartu, Tartu, Estonia.
  • Huik K; High Performance Computing Centre, Faculty of Science and Technology, Institute of Computer Science, University of Tartu, Tartu, Estonia.
PLoS One ; 19(5): e0303176, 2024.
Article en En | MEDLINE | ID: mdl-38728305
ABSTRACT

BACKGROUND:

The COVID-19 pandemic was characterised by rapid waves of disease, carried by the emergence of new and more infectious SARS-CoV-2 virus variants. How the pandemic unfolded in various locations during its first two years has yet to be sufficiently covered. To this end, here we are looking at the circulating SARS-CoV-2 variants, their diversity, and hospitalisation rates in Estonia in the period from March 2000 to March 2022.

METHODS:

We sequenced a total of 27,550 SARS-CoV-2 samples in Estonia between March 2020 and March 2022. High-quality sequences were genotyped and assigned to Nextstrain clades and Pango lineages. We used regression analysis to determine the dynamics of lineage diversity and the probability of clade-specific hospitalisation stratified by age and sex.

RESULTS:

We successfully sequenced a total of 25,375 SARS-CoV-2 genomes (or 92%), identifying 19 Nextstrain clades and 199 Pango lineages. In 2020 the most prevalent clades were 20B and 20A. The various subsequent waves of infection were driven by 20I (Alpha), 21J (Delta) and Omicron clades 21K and 21L. Lineage diversity via the Shannon index was at its highest during the Delta wave. About 3% of sequenced SARS-CoV-2 samples came from hospitalised individuals. Hospitalisation increased markedly with age in the over-forties, and was negligible in the under-forties. Vaccination decreased the odds of hospitalisation in over-forties. The effect of vaccination on hospitalisation rates was strongly dependent upon age but was clade-independent. People who were infected with Omicron clades had a lower hospitalisation likelihood in age groups of forty and over than was the case with pre-Omicron clades regardless of vaccination status.

CONCLUSIONS:

COVID-19 disease waves in Estonia were driven by the Alpha, Delta, and Omicron clades. Omicron clades were associated with a substantially lower hospitalisation probability than pre-Omicron clades. The protective effect of vaccination in reducing hospitalisation likelihood was independent of the involved clade.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 / Hospitalización Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Europa Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 / Hospitalización Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Europa Idioma: En Año: 2024 Tipo del documento: Article